Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics Inc. (Nasdaq: CMPX) advances novel antibody therapies targeting cancer's complex biology through its clinical-stage pipeline. This dedicated news center provides investors and researchers with essential updates on oncology developments, trial milestones, and scientific breakthroughs.
Access timely reports on bispecific antibody programs, including Tovecimig (CTX-009) for biliary tract cancers and CTX-471's CD137 agonist mechanism. Track regulatory progress across multiple indications and discover partnership announcements leveraging Compass' StitchMabs platform technology.
Our curated news collection serves as your primary source for:
- Phase 1-3 clinical trial updates
- FDA submissions and international regulatory milestones
- Peer-reviewed research publications
- Strategic collaborations in immuno-oncology
Bookmark this page for real-time insights into Compass' work on angiogenesis modulation and tumor microenvironment targeting. Monitor biomarker-driven developments that could shape next-generation cancer treatments.
Compass Therapeutics, Inc. (Nasdaq: CMPX) will host a webinar on May 4, 2022, at 8:00 a.m. ET to discuss clinical data from its ongoing Phase 2 trial of CTX-009. A Key Opinion Leader will join the management for this review. The company focuses on developing proprietary antibody-based therapeutics targeting cancer through a unique approach addressing angiogenesis and immune response. The upcoming session aims to provide insights into trial results, with a replay available for six months on the company's website.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced the appointment of two new directors, Ellen Chiniara and Mary Ann Gray, to its board. Chiniara, former Chief Legal Officer of Alexion Pharmaceuticals, and Gray, President of Gray Strategic Advisors, bring extensive experience in the life sciences and biopharmaceutical sectors. This strategic move aims to enhance Compass's leadership at a critical time for the company. The board believes their skills will support Compass in advancing its clinical pipeline and driving shareholder value.
Compass Therapeutics (CMPX), a clinical-stage oncology company, recently presented promising preclinical data for its bispecific checkpoint inhibitor, CTX-8371, at the AACR Annual Meeting. This innovative therapy targets both PD-1 and PD-L1, showcasing a unique mechanism of action that leads to PD-1 loss on T cells. Key findings indicate significant tumor volume reduction and complete tumor eradication in mouse models. Clinical development of CTX-8371 is projected to start in early 2023, marking a significant step forward in cancer therapeutics.
Compass Therapeutics Inc. (Nasdaq: CMPX) announced its presentation of preclinical data on CTX-8371, a bispecific checkpoint inhibitor targeting PD-1 and PD-L1, at the AACR Annual Meeting from April 8-13, 2022. The study, led by Diana Albu, Ph.D., will showcase the antibody's potential to enhance anti-tumor activity in solid tumors by converting PD-1-positive cells to PD-1-negative cells. As part of IND-enabling preclinical development, CTX-8371 shows promise over existing monoclonal antibodies, indicating its unique mechanism could mitigate immune suppression effectively.
Compass Therapeutics reported a strong financial position with $144.5 million in cash as of 2021, bolstered by a $136 million public offering. The company is advancing its clinical pipeline, particularly the CTX-009 study for advanced biliary tract cancers, which met response criteria for progression to Phase 2. Additionally, CTX-471 showed encouraging results in patients with solid tumors. However, the company faced a net loss of $82.2 million for 2021, with R&D expenses rising significantly to $20.3 million, marking a 36% increase from 2020. The company expects to sustain operations into late 2024.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced the FDA has cleared its IND application for CTX-009, enabling a global Phase 2 trial for Biliary Tract Cancers (BTC) in the U.S. and South Korea. CTX-009 is a bispecific antibody targeting DLL4 and VEGF-A, showing clinical benefit in heavily pre-treated patients. The ongoing Phase 2 study in South Korea has completed Stage 1, achieving a 29% overall response rate and a 100% clinical benefit rate. Expansion to U.S. sites is planned for Q2 2022, presenting potential growth opportunities for the company.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced that CEO Thomas Schuetz will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, from 8:15 to 8:55 a.m. ET. The presentation will be virtual, with details to be updated on the company's investor webpage. Compass Therapeutics focuses on antibody-based therapeutics for cancer treatment, exploring the interplay between angiogenesis, the immune system, and tumor growth. Established in 2014 and based in Boston, Massachusetts, the company aims to advance its innovative pipeline through clinical development.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced that CEO Thomas J. Schuetz, MD, PhD, will present at the Piper Sandler 33rd Annual Healthcare Conference held virtually from November 29 to December 2, 2021. The presentation will be available on-demand from November 22 to December 2, 2021. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics targeting cancer through modulating immune responses and angiogenesis. Founded in 2014 and based in Boston, Massachusetts, the company aims to advance its clinical pipeline.
Compass Therapeutics reported progress in its clinical studies and financial results for Q3 2021. The company advanced CTX-009 to the second stage of a Phase 2a study, with a 29% overall response rate observed in 17 patients. CTX-471 demonstrated two partial responses in melanoma patients. The recent public offering raised $125 million, extending its cash runway into Q4 2024. R&D expenses decreased to $3.2 million, and general and administrative expenses dropped to $2.7 million. The net loss was $6 million, or $0.10 per share, an improvement from the previous year.
Compass Therapeutics, Inc. announced a public offering of 35,715,000 shares at $3.50 each, expected to raise approximately $125 million. The offering will close on November 4, 2021, and includes an option for underwriters to purchase an additional 5,357,250 shares. This follows the company's listing on the Nasdaq Capital Market under the symbol CMPX, effective November 2, 2021. Proceeds will fund ongoing clinical trials and operations. SVB Leerink is the book-running manager for the offering.
